This website is for UK Healthcare Professionals only

+30 YEARS' GLOBAL EXPERIENCE ACROSS MULTIPLE INDICATIONS1-4

 

CHRONIC MIGRAINE

BOTOX® (botulinum toxin type A) is indicated for the prophylaxis of headaches in adults with chronic migraine (headaches on at least 15 days per month of which at least 8 days are with migraine).5

Guidelines recommend BOTOX® as a treatment option in the management of chronic migraine6,7


CG: clinical guideline; CM: chronic migraine; NICE: National Institute for Health and Care Excellence; SMC: Scottish Medicine Consortium; TAG: technology appraisal guidance.


BOTOX® (botulinum toxin type A) is indicated for the prophylaxis of headaches in adults with chronic migraine (headaches on at least 15 days per month of which at least 8 days are with migraine).5


 

© NICE [2012] Botulinum toxin type A for the prevention of headaches in adults with chronic migraine. Available from nice.org.uk. All rights reserved. Subject to Notice of rights

NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.

 

References

  1. AbbVie Data on file. Approval Dates for BOTOX® in UK. UK-BTX-230044. April 2023
  2. Allergan. Data on file. INT/0423/2016
  3. Aurora S K, Winner P et al. Onabotulinum toxin A for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Headache. 2011;51(9):1358-1373
  4. Blumenfeld A M, Stark R J et al. Long-term study of the efficacy and safety of Onabotulinum toxin A for the prevention of chronic migraine: COMPEL study. J Headache Pain. 2018;19(1):13
  5. BOTOX® Summary of Product Characteristics. Available from: https://www.medicines.org.uk/emc/product/859/smpc. Accessed April 2024
  6. National Institute for Health and Care Excellence (NICE). TA260: Botulinum toxin type A for the prevention of headaches in adults with chronic migraine. Available at: www.nice.org.uk. Accessed April 2024
  7. Scottish Medicines Consortium (SMC) Medicines advice: botulinum toxin A (Botox). SMC 692/11. Available at: www.scottishmedicines.org.uk. Accessed April 2024 

 

 

References

  1. AbbVie Data on file. Approval Dates for BOTOX® in UK. UK-BTX-230044. April 2023
  2. Allergan. Data on file. INT/0423/2016
  3. Aurora S K, Winner P et al. Onabotulinum toxin A for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Headache. 2011;51(9):1358-1373
  4. Blumenfeld A M, Stark R J et al. Long-term study of the efficacy and safety of Onabotulinum toxin A for the prevention of chronic migraine: COMPEL study. J Headache Pain. 2018;19(1):13
  5. BOTOX® Summary of Product Characteristics. Available from: https://www.medicines.org.uk /emc/product/859/smpc. Accessed April 2024
  6. National Institute for Health and Care Excellence (NICE). TA260: Botulinum toxin type A for the prevention of headaches in adults with chronic migraine. Available at: www.nice.org.uk. Accessed April 2024
  7. Scottish Medicines Consortium (SMC) Medicines advice: botulinum toxin A (Botox). SMC 692/11. Available at: www.scottishmedicines.org.uk. Accessed April 2024 

 

Please refer to the BOTOX® Summary of Product Characteristics for further information on adverse events, contraindications and special warnings and precautions for use.

 

 

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk

Adverse events should also be reported to AbbVie on [email protected] 

 

Date of preparation: April 2024. UK-BCM-240042.